684 related articles for article (PubMed ID: 22622492)
1. Update on fibroblast growth factor 23 in chronic kidney disease.
Wolf M
Kidney Int; 2012 Oct; 82(7):737-47. PubMed ID: 22622492
[TBL] [Abstract][Full Text] [Related]
2. Fibroblast growth factor 23: associations with cardiovascular disease and mortality in chronic kidney disease.
Negri AL
Int Urol Nephrol; 2014 Jan; 46(1):9-17. PubMed ID: 23296792
[TBL] [Abstract][Full Text] [Related]
3. Impact of fractional phosphate excretion on the relation of FGF23 with outcome in CKD patients.
Bech AP; Bouma-de Krijger A; van Zuilen AD; Bots ML; van den Brand JA; Blankestijn PJ; Wetzels JF; Vervloet MG
J Nephrol; 2015 Aug; 28(4):477-84. PubMed ID: 25700931
[TBL] [Abstract][Full Text] [Related]
4. FGF23 and Phosphate-Cardiovascular Toxins in CKD.
Vogt I; Haffner D; Leifheit-Nestler M
Toxins (Basel); 2019 Nov; 11(11):. PubMed ID: 31698866
[TBL] [Abstract][Full Text] [Related]
5. Associations of fibroblast growth factor 23, vitamin D and parathyroid hormone with 5-year outcomes in a prospective primary care cohort of people with chronic kidney disease stage 3.
Shardlow A; McIntyre NJ; Fluck RJ; McIntyre CW; Taal MW
BMJ Open; 2017 Aug; 7(8):e016528. PubMed ID: 28838895
[TBL] [Abstract][Full Text] [Related]
6. Fibroblast growth factor 23 is elevated before parathyroid hormone and phosphate in chronic kidney disease.
Isakova T; Wahl P; Vargas GS; Gutiérrez OM; Scialla J; Xie H; Appleby D; Nessel L; Bellovich K; Chen J; Hamm L; Gadegbeku C; Horwitz E; Townsend RR; Anderson CA; Lash JP; Hsu CY; Leonard MB; Wolf M
Kidney Int; 2011 Jun; 79(12):1370-8. PubMed ID: 21389978
[TBL] [Abstract][Full Text] [Related]
7. Reduced renal α-Klotho expression in CKD patients and its effect on renal phosphate handling and vitamin D metabolism.
Sakan H; Nakatani K; Asai O; Imura A; Tanaka T; Yoshimoto S; Iwamoto N; Kurumatani N; Iwano M; Nabeshima Y; Konishi N; Saito Y
PLoS One; 2014; 9(1):e86301. PubMed ID: 24466013
[TBL] [Abstract][Full Text] [Related]
8. FGF23 and Klotho in chronic kidney disease.
Olauson H; Larsson TE
Curr Opin Nephrol Hypertens; 2013 Jul; 22(4):397-404. PubMed ID: 23666415
[TBL] [Abstract][Full Text] [Related]
9. Fibroblast growth factor 23 and adverse clinical outcomes in chronic kidney disease.
Isakova T
Curr Opin Nephrol Hypertens; 2012 May; 21(3):334-40. PubMed ID: 22487610
[TBL] [Abstract][Full Text] [Related]
10. FGF23: a mature renal and cardiovascular risk factor?
Zoccali C; Yilmaz MI; Mallamaci F
Blood Purif; 2013; 36(1):52-7. PubMed ID: 23735695
[TBL] [Abstract][Full Text] [Related]
11. Endocrine fibroblast growth factors as potential biomarkers for chronic kidney disease.
Kondo Y; Komaba H; Fukagawa M
Expert Rev Mol Diagn; 2020 Jul; 20(7):715-724. PubMed ID: 32513031
[TBL] [Abstract][Full Text] [Related]
12. Inflammation and elevated levels of fibroblast growth factor 23 are independent risk factors for death in chronic kidney disease.
Munoz Mendoza J; Isakova T; Cai X; Bayes LY; Faul C; Scialla JJ; Lash JP; Chen J; He J; Navaneethan S; Negrea L; Rosas SE; Kretzler M; Nessel L; Xie D; Anderson AH; Raj DS; Wolf M;
Kidney Int; 2017 Mar; 91(3):711-719. PubMed ID: 28017325
[TBL] [Abstract][Full Text] [Related]
13. Fibroblast growth factor 23 and new-onset chronic kidney disease in the general population: the Prevention of Renal and Vascular Endstage Disease (PREVEND) study.
De Jong MA; Eisenga MF; van Ballegooijen AJ; Beulens JWJ; Vervloet MG; Navis G; Gansevoort RT; Bakker SJL; De Borst MH
Nephrol Dial Transplant; 2021 Jan; 36(1):121-128. PubMed ID: 32124925
[TBL] [Abstract][Full Text] [Related]
14. Phosphate, fibroblast growth factor 23 and retinopathy in chronic kidney disease: the Chronic Renal Insufficiency Cohort Study.
Mehta R; Ying GS; Houston S; Isakova T; Nessel L; Ojo A; Go A; Lash J; Kusek J; Grunwald J; Wolf M;
Nephrol Dial Transplant; 2015 Sep; 30(9):1534-41. PubMed ID: 25910495
[TBL] [Abstract][Full Text] [Related]
15. The FGF23-Klotho axis and cardiac tissue Doppler imaging in pediatric chronic kidney disease-a prospective cohort study.
Tranæus Lindblad Y; Olauson H; Vavilis G; Hammar U; Herthelius M; Axelsson J; Bárány P
Pediatr Nephrol; 2018 Jan; 33(1):147-157. PubMed ID: 28795324
[TBL] [Abstract][Full Text] [Related]
16. Simultaneous management of disordered phosphate and iron homeostasis to correct fibroblast growth factor 23 and associated outcomes in chronic kidney disease.
Courbon G; Martinez-Calle M; David V
Curr Opin Nephrol Hypertens; 2020 Jul; 29(4):359-366. PubMed ID: 32452919
[TBL] [Abstract][Full Text] [Related]
17. Single Measurements of Carboxy-Terminal Fibroblast Growth Factor 23 and Clinical Risk Prediction of Adverse Outcomes in CKD.
Edmonston D; Wojdyla D; Mehta R; Cai X; Lora C; Cohen D; Townsend RR; He J; Go AS; Kusek J; Weir MR; Isakova T; Pencina M; Wolf M;
Am J Kidney Dis; 2019 Dec; 74(6):771-781. PubMed ID: 31445926
[TBL] [Abstract][Full Text] [Related]
18. Increased FGF23 protects against detrimental cardio-renal consequences during elevated blood phosphate in CKD.
Clinkenbeard EL; Noonan ML; Thomas JC; Ni P; Hum JM; Aref M; Swallow EA; Moe SM; Allen MR; White KE
JCI Insight; 2019 Feb; 4(4):. PubMed ID: 30830862
[TBL] [Abstract][Full Text] [Related]
19. Rationale and Approaches to Phosphate and Fibroblast Growth Factor 23 Reduction in CKD.
Isakova T; Ix JH; Sprague SM; Raphael KL; Fried L; Gassman JJ; Raj D; Cheung AK; Kusek JW; Flessner MF; Wolf M; Block GA
J Am Soc Nephrol; 2015 Oct; 26(10):2328-39. PubMed ID: 25967123
[TBL] [Abstract][Full Text] [Related]
20. The role of fibroblast growth factor-23 in cardiorenal syndrome.
Kovesdy CP; Quarles LD
Nephron Clin Pract; 2013; 123(3-4):194-201. PubMed ID: 23942553
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
